Lifeboat Foundation

Central learning and memory hubs change in response to sex hormones. A new study in Nature Mental Health by Rachel Zsido and Julia Sacher of the Max Planck Institute for Human Cognitive and Brain Sciences and the University Clinic in Leipzig, Germany, links rhythmic oscillations in ovarian hormone levels in women during the menstrual cycle to changes in brain structure.

Ovarian hormones have significant effects on the brain, and early menopause may be associated with an increased risk of accelerated brain aging and dementia later in life. However, the effects of ovarian hormone fluctuations on brain structure earlier in life are less defined. In their current study, Zsido and Sacher show that fluctuations in ovarian hormones affect structural plasticity in key brain regions during the reproductive years.

To do this, the scientists collected blood samples from 27 female study participants, used ultrasound to track follicle growth in the ovaries to pinpoint ovulation timing, and utilized ultra-high field 7 Tesla MRI to zoom into subregions of the medial temporal lobe and hippocampus. That’s because these regions are dense with sex hormone receptors and are critical for cognitive function, such as episodic memory.

VIEW NOW: https://ow.ly/GMX050PMTMH

In this webinar, three experts will discuss how Precision NanoSystems’ modular microfluidic platform technologies and analytics can help scientists successfully design, develop, test, and scale-up promising mRNA-LNP vaccines and therapeutics from concept to clinic. Don’t miss this webinar, now available on demand.

Alreadyed? Click Here

Nucleic acids (e.g., siRNA, mRNA and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases. The recent commercialization and widespread distribution of COVID-19 mRNA vaccines has exemplified the massive potential of this new class of genomic medicines and vaccines to effectively thwart emerging viral threats and treat a wide range of challenging diseases. Part of developing a successful mRNA therapeutic or vaccine is choosing a delivery mechanism that protects the nucleic acids on the way to their target tissue. Encapsulating mRNA in lipid nanoparticles has proven to be one of the best vehicles for overcoming extracellular and intracellular barriers and safely delivering the treatment. Several mRNA-LNP formulations that target things like viral infections and cancers are being evaluated clinically.

Continue reading “Accelerating mRNA-LNP Medicine Development from Concept to Clinic” »

Researchers at Columbia University have developed a probiotic-guided chimeric antigen receptor (CAR)-T platform that uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find, identify, and destroy tumor cells in situ. The results of in vivo preclinical tests suggest that the combined ProCAR cell therapy platform could expand the scope of CAR-T cell therapy to include difficult-to-target solid tumors.

Tal Danino, PhD, and Rosa L. Vincent, PhD, at Columbia University’s department of biomedical engineering, and colleagues, reported on their developments in Science, in a paper titled “Probiotic-guided CAR-T cells for solid tumor targeting,” in which they concluded, “These findings highlight the potential of the ProCAR platform to address the roadblock of identifying suitable CAR targets by providing an antigen that is orthogonal to both healthy tissue and tumor genetics … Overall, combining the advantages of tumor-homing bacteria and CAR-T cells provides a new strategy for tumor recognition and, in turn, builds the foundation for engineered communities of living therapies.”

Immunotherapies using CAR-T cells have proven successful in treating some types of blood cancers, but their efficacy against solid tumors remains elusive. A key challenge facing tumor-antigen targeting immunotherapies like CAR-T is the identification of suitable targets that are specifically and uniformly expressed on solid tumors, the authors noted. “A key challenge of antigen-targeted cell therapies relates to the expression patterns of the antigen itself, which makes the identification of optimal targets for solid tumor cell therapies an obstacle for the development of new CARs.” Solid tumors express heterogeneous and nonspecific antigens and are poorly infiltrated by T cells. As a result, the approach carries a high risk of fatal on-target, off-tumor toxicity, wherein CAR-T cells attack the targeted antigen on healthy vital tissues with potentially fatal effects.

In the realm of healthcare, change has always been met with resistance. It took considerable time for the medical community to accept the stethoscope as a valuable tool in patient care. Similarly, it will take a while for Artificial Intelligence (AI) to be recognized as a full-fledged health tool, despite its immense potential to revolutionize the healthcare industry. However, when A.I. eventually takes its rightful place in healthcare, it will displace the stethoscope as its symbol. Let’s dive into how AI is poised to transform the way we approach healthcare.

Inflammatory bowel disease (IBD) is a major global health concern, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects. A major reason clinically successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.

In this webinar brought to you by Altis Biosystems, Bryan McQueen will describe the development of a new stem-cell derived intestinal epithelium model system for testing IBD therapeutic efficacy. Using this model system, researchers developed a suite of assays to probe epithelial barrier disruption, cytotoxicity, and pro-inflammatory cytokine release in response to the activation of prototypical IBD-associated cellular pathways.

In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, and other institutions found that nongenetic mechanisms are important in lung cancer patients who develop a resistance to one cancer therapy. Their findings were published in the October 13 issue of the journal Science Advances.

The team’s study explored resistance to the anti-cancer medication sotorasib in patients with non-small cell lung cancer (NSCLC). Sotorasib inhibits a specific mutation of a protein, KRAS G12C, that causes unchecked cell growth.

The researchers’ findings suggest that, initially, most tumor cells are sensitive to sotorasib. But some cells can become tolerant to therapeutic treatment without resorting to genetic mutations or alterations by manipulating the KRAS-sotorasib interaction network. Furthermore, they found that if sotorasib treatment is withheld, the tumor cells revert to becoming sensitive again, implying that the phenomenon is reversible and thus is driven by nongenetic mechanisms.

Feizi and his coauthors looked at how easy it is for bad actors to evade watermarking attempts. (He calls it “washing out” the watermark.) In addition to demonstrating how attackers might remove watermarks, the study shows how it’s possible to add watermarks to human-generated images, triggering false positives. Released online this week, the preprint paper has yet to be peer-reviewed, but Feizi has been a leading figure in AI detection, so it’s worth paying attention to, even at this early stage.

It’s timely research. Watermarking has emerged as one of the more promising strategies to identify AI-generated images and text. Just as physical watermarks are embedded on paper money and stamps to prove authenticity, digital watermarks are meant to trace the origins of images and text online, helping people spot deepfaked videos and bot-authored books. With the US presidential elections on the horizon in 2024, concerns over manipulated media are high—and some people are already getting fooled. Former US president Donald Trump, for instance, shared a fake video of Anderson Cooper on his Truth Social platform; Cooper’s voice had been AI-cloned.

This summer, OpenAI, Alphabet, Meta, Amazon, and several other major AI players pledged to develop watermarking technology to combat misinformation. In late August, Google’s DeepMind released a beta version of its new watermarking tool, SynthID. The hope is that these tools will flag AI content as it’s being generated, in the same way that physical watermarking authenticates dollars as they’re being printed.

According to this information covid 19 sars is a chimeric virus that evolves with other genetic material which gives us clues for a proper antidote. Also it shows why it is so dangerous.

Ben Hu denies he was sick in late 2019, or that his coronavirus work led to COVID-19, and newly declassified U.S. intelligence doesn’t substantiate allegations against him.

A study finds a material that is 120 times faster than similar ones, demonstrating its precision in remotely stimulating neurons and repairing severed sciatic nerves in rats.

A new study is paving the way for alternative approaches to treating brain and nerve problems gently without the need for major surgery by introducing a magnetoelectric material.

Despite challenges such as nerve cells not responding well to the signals made by these materials, Researchers wanted to find a way to make these signals easier for our nerves to understand.